About Arbutus Biopharma Corporation
https://www.arbutusbio.comArbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States.
CEO
Lindsay Androski
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2010-11-04 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 118
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
MORGAN STANLEY
Shares:24.45M
Value:$116.87M
WHITEFORT CAPITAL MANAGEMENT, LP
Shares:13.34M
Value:$63.78M
BLACKROCK, INC.
Shares:12.68M
Value:$60.6M
Summary
Showing Top 3 of 195
About Arbutus Biopharma Corporation
https://www.arbutusbio.comArbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $529K ▼ | $8.81M ▼ | $-7.74M ▼ | -1.46K% ▼ | $-0.04 ▼ | $-7.71M ▼ |
| Q2-2025 | $10.74M ▲ | $9.25M ▼ | $2.52M ▲ | 23.49% ▲ | $0.01 ▲ | $2.56M ▲ |
| Q1-2025 | $1.76M ▲ | $27.46M ▲ | $-24.53M ▼ | -1.39K% ▼ | $-0.13 ▼ | $-24.16M ▼ |
| Q4-2024 | $1.57M ▲ | $6.7M ▼ | $-12.53M ▲ | -796.19% ▲ | $-0.07 ▲ | $-15.34M ▲ |
| Q3-2024 | $1.34M | $22.78M | $-19.72M | -1.47K% | $-0.1 | $-19.35M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $93.7M ▼ | $97.71M ▼ | $20.31M ▲ | $77.4M ▼ |
| Q2-2025 | $98.09M ▼ | $103.27M ▼ | $20.29M ▼ | $82.98M ▲ |
| Q1-2025 | $112.71M ▼ | $117.01M ▼ | $37.85M ▲ | $79.16M ▼ |
| Q4-2024 | $122.62M ▼ | $131.71M ▼ | $34.34M ▲ | $97.37M ▼ |
| Q3-2024 | $127.79M | $140.44M | $33.55M | $106.89M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.74M ▼ | $-5.82M ▲ | $-10.02M ▼ | $844K ▲ | $-15M ▼ | $-5.82M ▲ |
| Q2-2025 | $2.52M ▲ | $-15.75M ▼ | $15.61M ▲ | $453K ▼ | $336K ▼ | $-15.75M ▼ |
| Q1-2025 | $-24.53M ▼ | $-13.39M ▼ | $11.35M ▼ | $2.78M ▲ | $746K ▼ | $-13.39M ▼ |
| Q4-2024 | $-12.53M ▲ | $-10.31M ▲ | $13.41M ▲ | $1.42M ▼ | $4.48M ▲ | $-10.4M ▲ |
| Q3-2024 | $-19.72M | $-20.74M | $-11.99M | $1.77M | $-30.94M | $-20.74M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
 NonCash Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Service Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Lindsay Androski
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2010-11-04 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 118
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
MORGAN STANLEY
Shares:24.45M
Value:$116.87M
WHITEFORT CAPITAL MANAGEMENT, LP
Shares:13.34M
Value:$63.78M
BLACKROCK, INC.
Shares:12.68M
Value:$60.6M
Summary
Showing Top 3 of 195